Product Description
Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. (Sourced from: https://investor.lilly.com/news-releases/news-release-details/tirzepatide-results-published-lancet-show-superior-a1c-and-body)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: Fast Track - Obesity|Obesity, Morbid|Overweight *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States
Approved Indications: Type 1 Diabetes | General Diabetes | Type 2 Diabetes
Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation | Diarrhea | Dyspepsia
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 65
Highest Development Phases
Phase 3: Apnea|Glucose Metabolism Disorders|Heart Failure, Chronic|Heart Failure, Diastolic|Obesity|Overweight|Sleep Apnea, Obstructive|Type 2 Diabetes|Weight Loss
Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Kidney Diseases|Kidney Failure, Chronic|Non-alcoholic Steatohepatitis|Wolfram Syndrome
Phase 1: Healthy Volunteers|Hypoglycemia|Pediatric Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Tirzepatide | P2 |
Not yet recruiting |
Overweight|Obesity |
2028-06-01 |
|
| jRCT2031220466 | P3 |
Recruiting |
Overweight|Obesity |
2027-11-30 |
|
| SURMOUNT-MMO | P3 |
Active, not recruiting |
Overweight|Obesity |
2027-10-07 |
72% |
| SURPASS-PEDS | P3 |
Active, not recruiting |
Type 2 Diabetes |
2027-01-22 |